Research programme: neurodegenerative disorders therapeutics - FORUM Pharmaceuticals

Drug Profile

Research programme: neurodegenerative disorders therapeutics - FORUM Pharmaceuticals

Alternative Names: EVP-0002442; EVP-2442; Neurodegenerative disorders therapeutics - EnVivo

Latest Information Update: 10 Apr 2014

Price : $50

At a glance

  • Originator EnVivo Pharmaceuticals
  • Developer CHDI; EnVivo Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neurodegenerative disorders

Most Recent Events

  • 02 Apr 2014 EnVivo Pharmaceuticals is now called FORUM Pharmaceuticals
  • 13 Feb 2008 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)
  • 30 Nov 2005 This research programme is available for licensing (http://www.envivopharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top